CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues, net of contractual allowances and adjustments	$ 3,448	$ 2,033
less allowance for doubtful accounts	(584)	(310)
Net sales	2,864	1,723
Service revenue	2,549	1,317
Clinical research grants	90	114
Total cost of sales	2,639	1,431
Gross profit	225	292
OPERATING EXPENSES:
Operating expenses	9,452	6,488
Impairment of goodwill	4,685	9,315
TOTAL OPERATING EXPENSES	14,137	15,803
OPERATING LOSS	(13,912)	(15,511)
OTHER INCOME (EXPENSE):
Interest expense, net	(269)	(2,324)
Warrant revaluation and modification	1,918	(226)
Derivative revaluation	267
Gain on settlement of liability, net	263	877
(Gain) loss on extinguishment of debt	376	(1,391)
Loss on extinguishment of convertible notes	(2,903)
Gain on troubled debt restructuring		1,181
Loss on issuance of convertible notes	(1,328)
Loss on settlement of equity instruments	(385)	(624)
Merger advisory fees		(2,676)
Other Income (Expense)	(2,061)	(5,183)
LOSS BEFORE INCOME TAXES	(15,973)	(20,694)
INCOME TAX BENEFIT	279	(349)
NET LOSS	(15,694)	(20,694)
Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock	(4,222)	(12,431)
Preferred dividends		(84)
TOTAL DIVIDENDS	(4,222)	(12,515)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (19,916)	$ (33,209)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)	$ (0.92)	$ (7.16)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)	21,616,702	4,639,226
Service revenue, net [Member]
Revenues, net of contractual allowances and adjustments	$ 3,335	$ 1,702
less allowance for doubtful accounts	(584)	(315)
Net sales	2,751	1,387
Clinical research grants [Member]
Revenues, net of contractual allowances and adjustments	100	278
Other [Member]
Revenues, net of contractual allowances and adjustments	$ 13	$ 53